Background Myocardial ouabain-binding sites and Na,KATPase activity are reduced in congestive heart failure (CHF), but the mechanisms by which CHF reduces the Na,K-ATPase remain unknown. We proposed to investigate whether the changes are accompanied by isoform-specific reductions of the Na,K-ATPase a-subunit proteins in CHF and whether similar changes could be produced by exogenous norepinephrine administration.
Methods and Results CHF was induced in dogs by rapid ventricular pacing at a rate of 225 beats per minute for 8 weeks (protocol 1). A second group of dogs were paced at 100 beats per minute and served as controls. In protocol 2, norepinephrine was infused in normal dogs using a subcutaneous osmotic minipump for 8 weeks. The control dogs received normal saline through the pump. Animals were studied after 8 weeks of pacing or norepinephrine infusion. After the baseline hemodynamics and interstitial norepinephrine concentration had been obtained, the hearts were removed for measuring [3H]ouabain-binding sites and Na,K-ATPase a-subunit proteins using isoform-specific monoclonal antibodies.
Tn he integral membrane-bound enzyme Na,KATPase is responsible for maintaining cell volume, ionic gradients, and membrane potential in a wide variety of cells.' It is also recognized as the receptor site for ouabain and other cardiac glycosides, which exert their action on the catalytic a-subunit of the enzyme to inhibit the Na,K-coupled transmembrane transport.2 Na,K-ATPase exists as a heterodimer composed of an a-and a P-subunit.' The catalytic unit of the enzyme resides in the a-subunit, which consists of three isoforms, each a product of its own gene. 3 The three isoforms differ in their antigenicity, migratory properties on SDS-PAGE, distribution in various tissues, level of expression during different developmental stages, binding affinity for ouabain, and susceptibility to the regulatory effects of hormones and pharmacological agents.3 The P-subunit exists in a one-to-one ratio with integration of the mature Na,K-ATPase into the plasma membrane. The ,8-subunit, by forming a complex with the a-subunit, also has been shown to prevent trypsinmediated degradation of the a-subunit. ' [3H]Ouabain-binding assay has been used to quantitate the abundance of Na,K-ATPase. It has been shown that myocardial ouabain-binding sites are reduced in patients with dilated cardiomyopathy. 4 Similarly, myocardial ouabain-binding sites and Na,K-ATPase activity are reduced in dogs with right heart failure produced by tricuspid avulsion and pulmonary artery constriction5 and in dogs with biventricular failure produced by rapid ventricular pacing. 6 The clinical implications of these observations are far-ranging given the multitude of roles that Na,K-ATPase plays in cellular functions and the widespread use of digitalis in the treatment of congestive heart failure (CHF). However, the ouabain-binding method does not distinguish the various isoforms of the Na,K-ATPase. In addition, the ouabain-binding properties and activity of the enzyme are affected by the concentrations of Na+, K', Ca2+, and Mg 2+ in the incubation medium. 7 In the present study, we proposed to investigate whether the myocardial Na,K-ATPase downregulation in CHF is limited to specific isoforms of the enzyme protein. We induced CHF in dogs using the rapid ventricular pacing technique. 8, 9 Using Western blot analysis, we were able to show that the reduction of myocardial ouabain-binding sites was associated with a decrease in Na,K-ATPase a-subunit protein and that the change in protein expression was isoform specific.
Furthermore, because the reduction of myocardial ouabain-binding sites in right heart failure could be prevented by }3-receptor blockade,5 we speculate that the changes in myocardial Na,K-ATPase in CHF are mediated via the sympathetic stimulation. Thus, we proposed in this study to determine whether norepinephrine infusion reduces myocardial ouabain-binding sites and Na,K-ATPase a-subunit isoforms. A subcutaneous osmotic minipump method10 was adopted to deliver norepinephrine to normal dogs. Finally, we used an intracoronary norepinephrine tracer technique" to measure myocardial interstitial norepinephrine concentration and to determine whether the Na,K-ATPase contents correlated with interstitial norepinephrine concentration in both the pacing-induced CHF and norepinephrine infusion studies.
Methods

Animal Preparation and Study Protocols
The study involved two different animal preparations: protocol 1 for pacing-induced CHF and protocol 2 for norepinephrine infusion experiments. Adult 
Plasma Norepinephrine Concentrations
Arterial blood was collected into ice-chilled glass tubes containing reduced glutathione. The blood was centrifuged, and the plasma was stored at -70°C for subsequent radioenzymatic norepinephrine assay.12
Myocardial Membrane Preparation
Muscle blocks (4 g) taken from the left ventricular free walls were trimmed, minced, and homogenized in an ice-cold 50 mmol/L Tris-HCl buffer (pH 7.4 at 22°C). The homogenate was centrifuged at 500g for 15 minutes at 4°C to remove nuclei and unbroken cells. The supernatant was collected and centrifuged again at 40 000g for 15 minutes at 4°C. The pellet then was resuspended in a buffer medium and filtered through a 53-jum nylon mesh. We have shown in pilot studies that the 50g pellets exhibit a much lower specific activity of 5'-nucleotidase (2.90±0.29 nmol adenosine . mg1 . min-', n=16) than the 40 00g pellets (16.9±0.73 nmol adenosine . mg-. minr', n= 16).
In addition, if the initial step of 50g centrifugation was omitted, the 40 00(0 pellet would have a much lower specific activity of 5'-nucleotidase (3.68±0.49 nmol adenosine . mg' . min-', n=15), suggesting that the low-speed centrifugation confers enrichment of the plasma membrane to the membrane preparation we used.
Measurement of 5'-Nucleotidase Activity
The activity of 5'-nucleotidase was determined using the method of Panagia et al. ' (Table 3) . Basal heart rate, however, was reduced significantly in the norepinephrine-infused dogs compared with the saline-infused dogs.
Fig 4 shows the effects of norepinephrine infusion on myocardial ouabain-binding sites and Na,K-ATPase isoform contents. As occurred in CHF dogs, myocardial ouabain receptor density was reduced in dogs after chronic norepinephrine infusion. There was no difference in the KD between the norepinephrine-and salineinfused dogs (13.2±+1.6 versus 12.6+±1.6 nmol/L). Concurrent with the change in ouabain receptor density was a reduction in the myocardial Na,K-ATPase a3 isoform of the norepinephrine-infused animals. In contrast, the a1 isoform protein did not differ for the two groups. Nor did the specific activity of 5'-nucleotidase differ significantly between the two groups (14.21 ± 1.71 versus 14.15±0.88 nmol adenosine . mg' -min').
Correlation Between Na,K-ATPase Isoforms and Interstitial Norepinephrine Concentrations
Myocardial interstitial norepinephrine concentrations were increased in CHF (1.12±0.15 ng/mL) and norepinephrine-infused (1.78±0.43 ng/mL) dogs compared with their respective sham-operated (0.20±0.07 ng/mL) and saline-infused (0.25±0.07 ng/mL) control groups. Fig 5 shows a negative correlation abundance of myocardial Na,K-ATPase a3 isoform and myocardial interstitial norepinephrine concentration in the CHF and norepinephrine infusion experiments (r=.57, P< .001). The coefficient of determination (r2) of .32 suggests that in this study population, 32% of the variation in myocardial Na,K-ATPase a3 isoform could be attributed to a linear association with interstitial norepinephrine concentration. In contrast, there was no significant correlation between interstitial norepinephrine concentration and Na,K-ATPase a, isoform content. Discussion
This study demonstrates the isoform-specific nature of downregulation of cardiac Na,K-ATPase in CHF. A marked reduction in the a3 isoform of the catalytic subunit was found with no alteration in the a1 isoform in cardiac tissue from dogs with pacing-induced CHF. We provided further evidence for the role of norepinephrine in mediating this downregulation by showing a similar isoform-specific reduction of the Na,K-ATPase in dogs with elevated circulating norepinephrine levels from chronic norepinephrine infusion without heart failure. Furthermore, a significant inverse correlation was found between myocardial interstitial norepinephrine concentration and the a3 isoform protein content in the CHF and norepinephrine infusion studies. In a previous study of right heart failure,5 we have shown that ouabain-binding sites are reduced not only in the hypertrophied failing right ventricle but also in the left ventricle, which has a normal or reduced filling pressure. These changes of ouabain-binding sites differ from those of myocardial 83-receptor density, which is reduced only in the failing right ventricle of our right heart failure animals23 or patients with pulmonary hypertension.24 The Our present study is the first to describe alterations of Na,K-ATPase isoforms in a canine model of heart failure. Isoform-specific changes of myocardial Na,KATPase also have been described in animals in response to developmental growth, physiological stimuli, and other pathological states. In rodents, there is a selective increase in the a2 isoform and decrease in the a3 isoform during normal postnatal development to young adulthood; the a, isoform remains unchanged.27 Thyroid hormone28 and insulin29 stimulate Na,K-ATPase enzyme activity and number in an isoform-specific manner. Cultured rat cardiocytes exposed to T3 displayed a preferential increase in the a, and a2 isoform mRNAs. The aC isoform mRNA initially increased but later decreased.30 A reduction of the a2 and a, isoform mRNA levels and an increase in the a, mRNA have been reported in the hypertrophied rat left ventricle.31 An isoform shift was also suggested in another study of cardiac hypertrophy,32 in which myocardial ouabainbinding characteristics and Na,K-ATPase activity changed to those resembling neonatal form. In addition, dogs sustaining myocardial infarctions demonstrated a preferential reduction of the a3 isoform.33 As in our present study, the a, isoform did not change significantly in the ischemic canine myocardium. Furthermore, the absence of a2 isoforms is not unique to the dog heart; the a2 isoform is also absent in the sheep, chicken, and guinea pig hearts.
Prior Wanless et a136 found that at the physiological concentration, norepinephrine stimulated Na,K-ATPase activity, but at the high doses it inhibited the Na,K-ATPase activity. The effects of norepinephrine on Na,K-ATPase also appear to be specific to the high-affinity isoform. 34 Thus, it appears that our results of norepinephrine infusion in intact dogs are consistent with the effects of chronic high-dose norepinephrine.
Further studies are needed of the time course or dose dependency of the effect of norepinephrine on the Na,K-ATPase isoform changes.
The dose of norepinephrine chosen for our studies was the same as that used previously in studying the effects of norepinephrine on the regulation of myocardial ,B-adrenoceptor-coupled adenylate cyclase in dogs.7 As demonstrated previously,7,37 despite the marked elevations in plasma norepinephrine, chronic norepinephrine infusion produced no significant increases in mean aortic pressure, left ventricular dP/dt, left atrial pressure, or left ventricular weight in dogs. Cardiac output also did not differ between the norepinephrine-and saline-infused animals. We have also found no histological evidence of hemorrhage or necrosis in the myocardium of the norepinephrine-infused animals (unpublished observations). However, basal heart rate was reduced after chronic norepinephrine infusion, probably because norepinephrine could either sensitize the aortic baroreceptor directly or increase systolic pressure enough to cause baroreflex-mediated slowing of the heart rate.
Our findings that norepinephrine infusion decreased myocardial ouabain-binding sites in dogs with normal left atrial pressure suggest that elevated filling pressure is not a prerequisite for the decrease in myocardial ouabain-binding sites. Results of our study indicate that an increase in interstitial norepinephrine to levels seen in CHF is sufficient to produce a decrease in myocardial ouabain-binding sites and the Na,K-ATPase a3 isoform protein level. However, only one third of the variations of myocardial Na,K-ATPase could be explained by the differences in interstitial norepinephrine concentrations in our present study, probably because significant biological individual variabilities exist in the relation between myocardial interstitial norepinephrine and Na,KATPase. A stronger correlation might exist between the two variables if interstitial norepinephrine and Na,KATPase could be measured serially in the same animals.
Our findings of norepinephrine infusion confirm the acute inhibitory effect of high-dose norepinephrine on Na,K-ATPase. 34 They also are consistent with the observations that chronic administration of ,3-adrenergic agonists reduces the density of ouabain-binding sites in guinea pig skeletal muscle. 38 The latter findings suggest that the effects of norepinephrine on ouabain-binding sites are not limited to the ventricular myocardium.
However, whether the 18-adrenergic agonists also produce isoform-specific changes on skeletal muscle Na,KATPase is not known.
Relatively little is known of the mechanisms by which norepinephrine modulates the molecular changes of the Na,K-ATPase enzyme. B3-Adrenoceptors appear to play a significant role in mediating the regulatory effects of norepinephrine since 1B-blockade prevents most, if not all, of the effects of norepinephrine.5,3435 Norepinephrine increases Na+ influx into the cells and may act to alter the Na,K-ATPase activity by changing intracellular Na+ and K' concentrations.7 Norepinephrine may also increase intracellular cAMP and inhibit Na,K-ATPase through a protein kinase A pathway involving phospholipase A2 and arachidonic acid release.3940 Phospholipase A2 has been shown to inhibit myocardial Na,KATPase activity and decrease the ouabain-binding sites by accumulation of endogenously produced lysophospholipids and nonesterified fatty acids and membrane phospholipid depletion.41 Furthermore, Na,K-ATPase can be inhibited by oxygen free radicals and oxidants. 42, 43 One possible mechanism of action of ,B-adrenoceptorblocking agents in preventing the downregulation of Na,K-ATPase may be related to their antioxidant properties. 44 The physiological and pharmacological significance of the reduction of Na,K-ATPase and a3 isoform-specific downregulation of Na,K-ATPase in CHF has not been established. It has been shown that the positive inotropic effect of ouabain is well preserved in the isolated muscle preparations of failing human hearts. 45, 46 In a canine right heart failure model, we also have demonstrated that despite a 38% to 50% decrease in ouabainbinding sites, the failing myocardium retains the same responsiveness as the normal heart to the positive inotropic effect of acetylstrophanthidin.5 However, because Na,K-ATPase affects resting membrane potential and transmembrane fluxes of various ions, changes in myocardial Na,K-ATPase like those occurring in CHF may influence important cardiac function and lead to certain functional alterations, such as potentiation of the arrhythmogenic effect of cardiac glycosides. The increase in arrhythmogenic transient depolarization that occurs in isoproterenol-induced cardiac hypertrophy47 could also be caused by the reduced myocardial ouabain-binding sites. Recently, using in situ hybridization techniques, Zahler et al48 have shown in adult rat hearts that the mRNAs for the a2 and a3 isoforms of the Na,K-ATPase are preferentially localized to the cardiac conduction system. Additional studies are warranted to delineate the anatomic distribution of Na,K-ATPase isoforms in other species and to determine whether a decrease in myocardial a3 Na,K-ATPase contributes to the development of cardiac dysfunction or the arrhythmogenic responses of the heart to cardiac glycosides in patients with CHF.
